Beijing, China/Bridgewater, New Jersey U.S, January 3, 2022 — Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced official appointment to Dr. Mike Hu as Chief Executive Officer and President of Gan & Lee Pharmaceuticals USA Corporation (hereinafter referred to as Gan & Lee USA). Dr. Hu will lead corporate Global Clinical Development and management of Gan & Lee USA.

Dr. Hu received his Doctor degree in Pharmaceutical Science from Shenyang Pharmaceutical University in China and completed his post-doctoral training in Yale University School of Medicine, research areas are molecular pharmacology and molecular biology. Dr. Hu has at present been engaged in Pre-clinical Development, Clinical Development, Global Regulatory Submissions and Approvals for innovative drug for multi-therapeutic areas, including Oncology, Hematology, Endocrinology, Metabolism, Anti-infective, and Rare Disease for more than 20 years. Prior to joining Gan & Lee, Dr. Hu was Chief Development Officer at Rafael Pharmaceuticals focusing on building pipelines for Oncology, Hematology and Rare Disease therapeutic areas. In his leadership position, Dr. Hu generated global pre-clinical and clinical development strategies, and established departments of Discovery, Pre-clinical Development, Clinical Development, Clinical Operation, Business Development, Regulatory Affairs, and CMC, leading more than 30 clinical trials and pre-clinical studies for CPI-613^®(devimistat) within 4 years, including 11 Phase  I/II studies and 2 Phase III studies.

Dr. Hu held a number of important leadership roles at Novartis, GlaxoSmithKline, and Jazz Pharmaceuticals. In these roles, he led 8 innovative drugs' global clinical development to market, and 11 on market drugs' life cycle management, across multi- therapeutic areas and various indications, covering up to multiple countries and areas, including China, U.S, E.U, Australia and Canada, made a great contribution to these companies' drug portfolios. Besides, Dr. Hu has extensive experience in business development and internal protocol review.

“We are very excited to have Dr. Hu join us at this critical time, as Gan & Lee has made a series of significant advances in the clinical development in China and the United States, and there will be more and more products to launch globally. Dr. Hu has worked at pharmaceutical companies of various scales. He has outstanding achievement in clinical development and rich experiences in cross-culture management, and he is passionate and persistent in his work,” said Kai Du, CEO of Gan & Lee, Chairman of Gan & Lee USA. “We believe Dr. Hu will be an invaluable leader to Gan & Lee, as we are aiming to grow and advance our innovative pipeline to serve patients worldwide.”

“Gan & Lee has made outstanding achievements in diabetes therapeutic areas, it has brought gospel to diabetics in China and around the world. In the past few years, Gan & Lee has never stopped advancing and exploring. It has actively engaged in the research field of Oncology, Immunity, Cardiovascular and Metabolic diseases. Meanwhile, it fully demonstrates its spirit and determination to take the domestic enterprise responsibility and adhere to the road of independent innovation, such a sense of mission is admirable,” Said Dr. Hu. “I am very glad to join the Gan & Lee's team to create a better future, to develop high-quality drugs for patients around the world. I sincerely hope that my ability and experience will inject new impetus into Gan & Lee and make contributions to Gan & Lee’s global business development.

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.